Does Rebif Cause Depression?
Rebif (interferon beta-1a) lists depression as a possible side effect, reported in clinical trials and post-marketing data. In pivotal trials like PRISMS and EVIDENCE, depression occurred in 20-25% of Rebif patients versus 14-16% on placebo or other interferons, though causality isn't always clear due to multiple sclerosis (MS) itself increasing depression risk.[1][2]
How Common Is Depression on Rebif?
Depression rates vary by dose and study:
- 44 mcg three times weekly: ~25% incidence.
- Lower doses: 18-20%.
Severe cases leading to suicidal ideation affected <1% in trials, but real-world reports note higher monitoring needs.[1][3] MS patients on Rebif face 1.5-2x higher depression odds than untreated MS patients, per observational data.[4]
Why Might Rebif Trigger Depression?
Interferons like Rebif boost cytokines (e.g., IFN-gamma), which can cross the blood-brain barrier and alter serotonin/dopamine pathways, mimicking flu-like symptoms that evolve into mood changes. Genetic factors (e.g., serotonin transporter variants) may heighten risk.[5] MS brain inflammation compounds this.
What Do Patients Report?
User forums and FDA adverse event reports (FAERS) show ~10-15% of Rebif complaints involve new or worsened depression, often starting weeks into treatment. Some describe "interferon blues" resolving after dose adjustment or switching drugs.[6]
How Does Rebif Compare to Other MS Drugs?
| Drug | Depression Rate in Trials | Notes |
|------|---------------------------|-------|
| Rebif (IFN beta-1a) | 20-25% | Higher neuropsychiatric effects |
| Avonex (IFN beta-1a) | 18-20% | Similar profile |
| Copaxone (glatiramer) | 10-15% | Lower mood impact |
| Ocrevus (ocrelizumab) | 5-8% | Minimal depression reports |
| Tecfidera (dimethyl fumarate) | 12-15% | More flushing than mood issues[1][7] |
Switching to non-interferon DMTs often reduces symptoms.
What Should You Do If Depression Starts?
Monitor mood weekly; report to your doctor immediately. Guidelines recommend screening with PHQ-9 at baseline and every 3 months. Options include antidepressants (SSRIs safe with Rebif), therapy, or drug holidays. Suicidality requires urgent ER visit.[2][8] No Rebif-specific patents tie to depression risks (generic entry eyed for 2026).[9]
[1]: Rebif Prescribing Information (EMD Serono)
[2]: PRISMS Study (Lancet, 1998)
[3]: EVIDENCE Study (Neurology, 2003)
[4]: MS Depression Review (Neurology, 2014)
[5]: Cytokine Mechanisms (J Neuroimmunol, 2010)
[6]: FDA FAERS Database
[7]: OCREVUS Label (Genentech)
[8]: AAN MS Guidelines (Neurology, 2018)
[9]: DrugPatentWatch: Rebif Patents